StemSight is at the forefront of developing innovative regenerative cell therapies aimed at curing corneal blindness, a condition that affects millions globally. The company specializes in creating off-the-shelf cell therapies that utilize induced pluripotent stem (iPS) cells combined with functional biomaterials. This approach is rooted in the groundbreaking research of Dr. Shinya Yamanaka, who pioneered the development of iPS cells known for their ability to self-renew and differentiate into various cell types. By leveraging this technology, StemSight aims to address the critical shortage of corneal tissue transplants and provide viable treatment options for conditions such as limbal stem cell deficiency (LSCD) and corneal endothelial dystrophies.

The primary focus of StemSight's research is on developing cell therapy products that can restore vision for patients suffering from LSCD, a severe condition that currently lacks effective treatment options. The company envisions creating a sustainable source of corneal cells that can be used to treat various forms of blindness, thereby significantly improving patient outcomes. With a strong foundation in regenerative medicine and tissue engineering, StemSight is well-positioned to advance its innovative therapies and contribute to the global health ecosystem, particularly in addressing unmet medical needs in ophthalmology.

Finland

StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials - for FASTER tissue regeneration, SAFER cell therapies and EASIER cell delivery.

StemSight

Company Details